Ambee Pharmaceuticals (DHA:AMBEEPHA) Return-on-Tangible-Asset: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:AMBEEPHA Ambee Pharmaceuticals Plc DHA:AMBEEPHA
18 GF Score
Price BDT791.50
View Full Analysis

What is Ambee Pharmaceuticals Return-on-Tangible-Asset?

Ambee Pharmaceuticals DHA:AMBEEPHA -1.86% 18 Return-on-Tangible-Asset is 0.00% as of . 20. GuruFocus rates DHA:AMBEEPHA with a GF Score™ of 18/100. Among 1,008 Drug Manufacturers companies, Ambee Pharmaceuticals ranks worse than 99206.25% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ambee Pharmaceuticals's annualized Net Income for the quarter that ended in . 20 was BDT Mil. Ambee Pharmaceuticals's average total tangible assets for the quarter that ended in . 20 was BDT Mil. Therefore, Ambee Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Ambee Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

DHA:AMBEEPHA's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.14
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Ambee Pharmaceuticals  (DHA:AMBEEPHA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Ambee Pharmaceuticals Return-on-Tangible-Asset Related Terms


Ambee Pharmaceuticals Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Ambee Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ambee Pharmaceuticals Return-on-Tangible-Asset Chart

Ambee Pharmaceuticals Annual Data
Trend
Return-on-Tangible-Asset

Ambee Pharmaceuticals Semi-Annual Data
Return-on-Tangible-Asset

DHA:AMBEEPHA vs IMNPQ: Return-on-Tangible-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ambee Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambee Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ambee Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Ambee Pharmaceuticals's Return-on-Tangible-Asset falls into.


DHA:AMBEEPHA
18GF Score
Ambee Pharmaceuticals Plc DHA:AMBEEPHA
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ambee Pharmaceuticals Return-on-Tangible-Asset Calculation

Ambee Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+)/ )
=/
= %

Ambee Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (. 20) net income data.

What does a Return-on-Tangible-Asset of 0.00% mean?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a Return-on-Tangible-Asset of 0.00% as of . 20. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ambee Pharmaceuticals and its competitors. According to the industry distribution chart, Ambee Pharmaceuticals ranks #999999 out of 1008 companies in the Drug Manufacturers industry.
Is Ambee Pharmaceuticals' Return-on-Tangible-Asset too high?
Ambee Pharmaceuticals' current Return-on-Tangible-Asset is 0.00%. Based on the distribution chart, Ambee Pharmaceuticals ranks #999999 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ambee Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Ambee Pharmaceuticals' Return-on-Tangible-Asset compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, Ambee Pharmaceuticals ranks #999999 out of 1008 companies for Return-on-Tangible-Asset. This places Ambee Pharmaceuticals in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.14, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ambee Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambee Pharmaceuticals's current Return-on-Tangible-Asset is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambee Pharmaceuticals stock overvalued right now?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a current Return-on-Tangible-Asset of 0.00%. The current Return-on-Tangible-Asset is 0.00%. Ambee Pharmaceuticals' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Ambee Pharmaceuticals (DHA:AMBEEPHA), the current Return-on-Tangible-Asset is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ambee Pharmaceuticals Business Description

Address 184/1 Tejgaon Industrial Area, Dhaka, BGD, 1208
Ambee Pharmaceuticals Plc formerly Ambee Pharmaceuticals Ltd manufactures a wide range of pharmaceutical products in Bangladesh. It is engaged in the business of manufacturing drugs and medicine and sales. Its products are sold in the form of tablets, capsules, liquids, gels, and injectables.
18GF Score

Get the complete analysis for DHA:AMBEEPHA

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT791.50
Price